Neurotherapeutics: The Next Wave
The Post-SSRI Transition: Evidence, Capital, and the Rapidly Closing Window In the neurotherapeutics sector, molecules were never the problem; strategy was. To elaborate on this premise, we brought three distinct evolving concepts together: the slowly crumbling SSRI paradigm, psychedelic compounds joining the clinical mainstream, and a closer look at the psilocybin landscape. The clinical picture […]